Non-peptide
Clascoterone
Also known as
Winlevi · Breezula · CB-03-01 · cortexolone 17α-propionate · clascoterone 1% · clascoterone 5%
Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.
What it is
| Topical androgen blocker | Clascoterone is discussed for hormonal acne and hair loss. Winlevi is 1% acne cream; Breezula is the scalp-development program, and CB-03-01 names the molecule. |
|---|---|
| Cream versus scalp solution | The carrier and concentration differ. Acne cream and scalp preparations cannot be treated as interchangeable products. |
Notes
Clascoterone is a topical androgen blocker discussed for hormonal acne and hair loss. Acne users describe fewer painful spots, unchanged skin, or irritation; hair users debate whether acne cream can substitute for a scalp solution. Reported benefit depends on the form and often comes alongside other treatments.
Winlevi, Breezula and CB-03-01 name the same molecule, not interchangeable products. Also called cortexolone 17α-propionate, it blocks androgen receptors in skin. Winlevi is 1% acne cream; Breezula names the higher-strength scalp-development program. Cream versus solution changes the carrier as well as concentration. Winlevi: European Medicines Agency overview (Official context · Accessed 2026-09-30) · SCALP2: NCT05914805 study registry (Official context · Accessed 2026-09-30)
The tube, dropper and comparisons cause practical confusion. Some acne users like the cream texture; others find it thick. Hair conversations compare clinic scalp preparations with pharmacy acne cream, RU and pyrilutamide. A fivefold concentration difference is not a fivefold effectiveness difference, and older minoxidil comparisons do not establish superiority or a finasteride replacement. Talk to me about clascoterone (Winlevi): good, bad and ugly (Community discussion · Accessed 2026-09-30) · Anyone tried Winlevi for hair loss? (Personal report · Accessed 2026-09-30)
Source context — Winlevi: European Medicines Agency overview: Current EU acne information. Pregnancy restriction and adolescent controls are jurisdiction-specific; no hair-loss approval inferred. Agency statement about growth/puberty outcomes is distinct from biochemical suppression found in the US maximal-use label.
Source context — SCALP2: NCT05914805 study registry: API response inspected directly through HTTPS after web extractor returned Internal Error. Registry design, not individual community practice, completed comparative outcome inspection or approval determination.
Source context — Talk to me about clascoterone (Winlevi): good, bad and ugly: Self-selected uncontrolled accounts; concurrent skincare, oral spironolactone and changing routines in some reports. Relative timestamps not converted to publication dates. No prevalence inference; a two-day response is one person's perception.
Source context — Anyone tried Winlevi for hair loss?: One uncontrolled null report, routinely shaved head and no standardized comparison. Proposed nine-month reassessment is not completed nine-month follow-up. No absolute month inferred from relative timestamps.
What people notice
| Acne | Some report fewer painful chin/jaw spots or less oil; others report no improvement after six weeks or two months. A promising start can later reverse. |
|---|---|
| Hair | Reports include maintenance alongside several treatments, no difference with nightly 1% cream, and less shedding with a roughly 15% solution whose sleep/energy problems led to stopping. |
Notes
Fewer painful acne spots, sometimes less oil. One commenter described smaller premenstrual jaw pimples and more even nose oil. Another described improved cystic chin acne while still using a separate acne product. Replies also include six weeks or two months without improvement: clearer skin is not everyone's experience. Talk to me about clascoterone (Winlevi): good, bad and ugly (Community discussion · Accessed 2026-09-30)
A promising start can reverse. The five-month acne account initially blamed an overloaded routine, simplified it, and sounded pleased before reporting relapse. A different commenter stopped after six weeks without benefit and reported no withdrawal. Both timelines matter when reading early enthusiasm. Talk to me about clascoterone (Winlevi): good, bad and ugly (Community discussion · Accessed 2026-09-30)
Hair maintenance is a different claim from regrowth. A long-running forum account describes maintaining hair alongside several treatments. A nightly acne-cream user noticed no hair difference. The 15% solution account describes less shedding, but sleep and energy problems outweighed the perceived benefit. Short Info On My CB Experience (in One Place) (Personal report · Accessed 2026-09-30) · Anyone tried Winlevi for hair loss? (Personal report · Accessed 2026-09-30) · CB-03-01 / Breezula Personal Results (Personal report · Accessed 2026-09-30)
Source context — Talk to me about clascoterone (Winlevi): good, bad and ugly: Self-selected uncontrolled accounts; concurrent skincare, oral spironolactone and changing routines in some reports. Relative timestamps not converted to publication dates. No prevalence inference; a two-day response is one person's perception.
Source context — Short Info On My CB Experience (in One Place): Historic single uncontrolled multi-treatment account. Self-claimed identity testing and hormone tests not independently inspected. Does not establish current product equivalence, efficacy or long-term safety. Solvent recipe and buying instructions not reproduced.
Source context — Anyone tried Winlevi for hair loss?: One uncontrolled null report, routinely shaved head and no standardized comparison. Proposed nine-month reassessment is not completed nine-month follow-up. No absolute month inferred from relative timestamps.
Source context — CB-03-01 / Breezula Personal Results: One unverified approximately15% research-product account. Product purity, dose, frequency and cortisol suppression not verified. Concurrent treatments and prior RU/pyrilutamide use confound hair and symptom attribution. Vendor and purchase details deliberately excluded from public copy.
Doses people talk about
| 1% cream | Acne accounts describe morning and evening use; one hair experiment used it nightly. Grams per application are absent, so daily milligrams cannot be reconstructed. |
|---|---|
| 2% scalp solution | One older log reports 50 mg in 2.5 mL daily. That is a solution's reported daily total, not a cream equivalent. |
| Higher-strength forms | Hair-study talk includes 5% twice daily; SCALP2 specified 1.5 mL per application. A separate roughly 15% whole-scalp account omits amount and frequency. |
Notes
1% acne cream: morning and evening in acne accounts; nightly in one hair experiment. The acne account also used tretinoin and a benzoyl-peroxide wash. The hair commenter used morning minoxidil. Neither supplied grams per application, so a daily milligram total cannot be reconstructed. Clascoterone 1% cream: how is it working out? (Community discussion · Accessed 2026-09-30) · Anyone tried Winlevi for hair loss? (Personal report · Accessed 2026-09-30)
2% scalp solution: 50 mg in 2.5 mL daily in one older log. This is a reported daily total, not a cream equivalent. Short Info On My CB Experience (in One Place) (Personal report · Accessed 2026-09-30)
5%, 7.5% and about 15% have different origins. The 5% twice-daily and earlier 2.5% or 7.5% numbers circulate from hair studies and clinic explainers. Separately, one user reported about 15% liquid over the whole scalp; amount and application frequency were unspecified. These do not form a dose ladder. CB-03-01 / Breezula Personal Results (Personal report · Accessed 2026-09-30)
Hair-study conditions are separately defined. SCALP2 specified 5% scalp solution, 1.5 mL per application twice daily, for six controlled months, with a separate six-month extension for responders. These are trial conditions, not community measurements or proof that acne cream treats hair loss. SCALP2: NCT05914805 study registry (Official context · Accessed 2026-09-30)
Source context — Clascoterone 1% cream: how is it working out?: Self-reported product concentrations and prior/concurrent treatments. Do not repeat the apparent tretinoin-strength typo as a verified dose. Clearing after stopping both drugs cannot isolate either effect.
Source context — Anyone tried Winlevi for hair loss?: One uncontrolled null report, routinely shaved head and no standardized comparison. Proposed nine-month reassessment is not completed nine-month follow-up. No absolute month inferred from relative timestamps.
Source context — Short Info On My CB Experience (in One Place): Historic single uncontrolled multi-treatment account. Self-claimed identity testing and hormone tests not independently inspected. Does not establish current product equivalence, efficacy or long-term safety. Solvent recipe and buying instructions not reproduced.
Source context — CB-03-01 / Breezula Personal Results: One unverified approximately15% research-product account. Product purity, dose, frequency and cortisol suppression not verified. Concurrent treatments and prior RU/pyrilutamide use confound hair and symptom attribution. Vendor and purchase details deliberately excluded from public copy.
Source context — SCALP2: NCT05914805 study registry: API response inspected directly through HTTPS after web extractor returned Internal Error. Registry design, not individual community practice, completed comparative outcome inspection or approval determination.
Half-life, onset & duration
| Felt onset | Some acne accounts notice changes within days or less oil around week four. Early perceived shedding changes do not establish new hair growth. |
|---|---|
| Felt duration | Repeated-use histories do not establish a single-application window. One acne user relapsed after initial improvement; another reported fewer cysts during six months of use. |
| Half-life | The record establishes no dependable community half-life. Twice-daily application and the label's day-five blood plateau do not measure it. |
Notes
Days in some accounts; weeks or no change in others. One acne reviewer noticed improvement within days; another commenter noticed slightly less oil around week four. The concentrated hair-solution user perceived less shedding within days, while the nightly 1% hair user remained unimpressed. Early appearance changes do not establish new hair growth. Winlevi patient reviews for acne (Personal report · Accessed 2026-09-30) · Talk to me about clascoterone (Winlevi): good, bad and ugly (Community discussion · Accessed 2026-09-30) · CB-03-01 / Breezula Personal Results (Personal report · Accessed 2026-09-30) · Anyone tried Winlevi for hair loss? (Personal report · Accessed 2026-09-30)
Repeated-use histories do not reveal single-application duration. One acne user initially improved, had about two weeks without new pimples, then relapsed and stopped around month five. Another reviewer reported fewer painful cysts during six months of use. Neither describes a lasting cure after stopping. Talk to me about clascoterone (Winlevi): good, bad and ugly (Community discussion · Accessed 2026-09-30) · Winlevi patient reviews for acne (Personal report · Accessed 2026-09-30)
No dependable community measurement in these accounts. Morning-and-night use is a reported application schedule, not a measured half-life. How long one skin application blocks receptors, blood elimination and how long an improvement lasts are separate questions. Clascoterone 1% cream: how is it working out? (Community discussion · Accessed 2026-09-30)
A blood plateau is not a half-life. The acne label reports stable blood levels by day five during repeated use. That does not give a dependable scalp-effect interval. WINLEVI (clascoterone) cream: US prescribing information (Official context · Accessed 2026-09-30)
Source context — Winlevi patient reviews for acne: User-submitted self-selected testimonials hosted on a commercial health-information platform; identity, diagnoses, dosing and co-treatment not verified. Selected positive reviews do not establish a response rate.
Source context — Talk to me about clascoterone (Winlevi): good, bad and ugly: Self-selected uncontrolled accounts; concurrent skincare, oral spironolactone and changing routines in some reports. Relative timestamps not converted to publication dates. No prevalence inference; a two-day response is one person's perception.
Source context — CB-03-01 / Breezula Personal Results: One unverified approximately15% research-product account. Product purity, dose, frequency and cortisol suppression not verified. Concurrent treatments and prior RU/pyrilutamide use confound hair and symptom attribution. Vendor and purchase details deliberately excluded from public copy.
Source context — Anyone tried Winlevi for hair loss?: One uncontrolled null report, routinely shaved head and no standardized comparison. Proposed nine-month reassessment is not completed nine-month follow-up. No absolute month inferred from relative timestamps.
Source context — Clascoterone 1% cream: how is it working out?: Self-reported product concentrations and prior/concurrent treatments. Do not repeat the apparent tretinoin-strength typo as a verified dose. Clearing after stopping both drugs cannot isolate either effect.
Source context — WINLEVI (clascoterone) cream: US prescribing information: Acne1% cream label, not a5% scalp or15% user-product label. Day5 plateau is not half-life, and maximal-use laboratory findings do not diagnose a forum user's fatigue. Supporting caution/identity only; no formal dose substituted into practical sections.
Cycles people discuss
| Ongoing use | Accounts describe continued use and stopping for nonresponse or unwanted effects, without a shared on/off or restart calendar. |
|---|---|
| Hair assessment | Three-to-six-month photo windows and a 2.5-year log are observation periods, not validated cycle lengths. |
Notes
Ongoing use and assessment windows, not a shared on/off cycle. The older hair notes use 3–6-month photo comparisons; one detailed log ran 2.5 years. These are observation periods, not validated course lengths. Acne users stopped for nonresponse or unwanted effects, and stopping experiences differ. No dependable break or restart calendar emerged. Short Info On My CB Experience (in One Place) (Personal report · Accessed 2026-09-30) · Talk to me about clascoterone (Winlevi): good, bad and ugly (Community discussion · Accessed 2026-09-30) · Beware the Winlevi withdrawal (Personal report · Accessed 2026-09-30)
Source context — Short Info On My CB Experience (in One Place): Historic single uncontrolled multi-treatment account. Self-claimed identity testing and hormone tests not independently inspected. Does not establish current product equivalence, efficacy or long-term safety. Solvent recipe and buying instructions not reproduced.
Source context — Talk to me about clascoterone (Winlevi): good, bad and ugly: Self-selected uncontrolled accounts; concurrent skincare, oral spironolactone and changing routines in some reports. Relative timestamps not converted to publication dates. No prevalence inference; a two-day response is one person's perception.
Source context — Beware the Winlevi withdrawal: Unverified self-attribution. No medical confirmation of topical steroid withdrawal. The opening says one year later, while TLDR describes six months to heal: prose retains months to recover without reconciling these into a precise duration. One OP and their timeline are one account.
Stacks
| Acne routines | Retinoids and benzoyl peroxide appear alongside the cream; combining irritating products can add skin reactions. |
|---|---|
| Hair routines | Minoxidil and finasteride/dutasteride appear in saved stack talk. One maintenance log also used progesterone, setipiprant and occasional light treatment; benefit cannot be assigned to one product. |
Notes
Acne routines: Retinoids and benzoyl peroxide appear beside clascoterone; several irritating products can contribute to a skin reaction. [community]
Dryness, redness, itching and burning. Other irritating acne products can add to skin reactions. The US label cautions about damaged skin, large areas and covering treated skin; it reports suppression of the body's cortisol-control system under maximal-use conditions. The 15% user's fatigue does not diagnose that condition. WINLEVI (clascoterone) cream: US prescribing information (Official context · Accessed 2026-09-30) · CB-03-01 / Breezula Personal Results (Personal report · Accessed 2026-09-30)
1% acne cream: morning and evening in acne accounts; nightly in one hair experiment. The acne account also used tretinoin and a benzoyl-peroxide wash. The hair commenter used morning minoxidil. Neither supplied grams per application, so a daily milligram total cannot be reconstructed. Clascoterone 1% cream: how is it working out? (Community discussion · Accessed 2026-09-30) · Anyone tried Winlevi for hair loss? (Personal report · Accessed 2026-09-30)
Hair combinations: Accounts include minoxidil and oral or topical finasteride/dutasteride. Their presence prevents a hair change from being assigned to clascoterone alone. [community]
Maintenance came with several treatments. In the separate 2.5-year maintenance account, hilbert used clascoterone alongside minoxidil, progesterone, setipiprant and occasional light treatment. They reported normal early hormone tests and fluctuating libido despite unchanged use; this is not the approximately 15% solution author's history. Short Info On My CB Experience (in One Place) (Personal report · Accessed 2026-09-30)
Source context — WINLEVI (clascoterone) cream: US prescribing information: Acne1% cream label, not a5% scalp or15% user-product label. Day5 plateau is not half-life, and maximal-use laboratory findings do not diagnose a forum user's fatigue. Supporting caution/identity only; no formal dose substituted into practical sections.
Source context — CB-03-01 / Breezula Personal Results: One unverified approximately15% research-product account. Product purity, dose, frequency and cortisol suppression not verified. Concurrent treatments and prior RU/pyrilutamide use confound hair and symptom attribution. Vendor and purchase details deliberately excluded from public copy.
Source context — Clascoterone 1% cream: how is it working out?: Self-reported product concentrations and prior/concurrent treatments. Do not repeat the apparent tretinoin-strength typo as a verified dose. Clearing after stopping both drugs cannot isolate either effect.
Source context — Anyone tried Winlevi for hair loss?: One uncontrolled null report, routinely shaved head and no standardized comparison. Proposed nine-month reassessment is not completed nine-month follow-up. No absolute month inferred from relative timestamps.
Source context — Short Info On My CB Experience (in One Place): Historic single uncontrolled multi-treatment account. Self-claimed identity testing and hormone tests not independently inspected. Does not establish current product equivalence, efficacy or long-term safety. Solvent recipe and buying instructions not reproduced.
Watch for
| Skin reactions | Dryness, redness, itching and burning are reported. One prolonged rash after stopping was compared with steroid withdrawal by its author, without a confirmed diagnosis. |
|---|---|
| Systemic uncertainty | The label reports cortisol-system suppression under maximal-use conditions. A concentrated solution user's fatigue does not diagnose that; topical use does not guarantee skin-only effects. |
| Pregnancy and combinations | The saved EU information prohibits pregnancy use. Clinical interaction studies and long-term safety evidence for unverified concentrated preparations remain absent. |
Notes
Dryness, redness, itching and burning. Other irritating acne products can add to skin reactions. The US label cautions about damaged skin, large areas and covering treated skin; it reports suppression of the body's cortisol-control system under maximal-use conditions. The 15% user's fatigue does not diagnose that condition. WINLEVI (clascoterone) cream: US prescribing information (Official context · Accessed 2026-09-30) · CB-03-01 / Breezula Personal Results (Personal report · Accessed 2026-09-30)
A severe stopping reaction is reported, not a confirmed diagnosis. One user described three good months, returning acne, then an itchy, red, dry rash three days after stopping. They described prolonged sensitivity and months to recover. Their comparison with topical steroid withdrawal does not establish that diagnosis or show how often it happens. Beware the Winlevi withdrawal (Personal report · Accessed 2026-09-30)
People want hormone-targeted skin or hair effects without an oral drug. Acne discussion centers on recurring chin and jaw breakouts. Hair discussion centers on maintenance without oral finasteride, and comparisons with RU-58841 or pyrilutamide. Topical application does not guarantee that effects stay entirely in the skin. Talk to me about clascoterone (Winlevi): good, bad and ugly (Community discussion · Accessed 2026-09-30) · CB-03-01 / Breezula Personal Results (Personal report · Accessed 2026-09-30)
Pregnancy and adolescents require distinct caution. EU information prohibits pregnancy use and restricts adolescent treatment to facial acne with monitoring precautions. Its authorization on 17 October 2025 superseded the earlier refusal while retaining endocrine precautions. Winlevi: European Medicines Agency overview (Official context · Accessed 2026-09-30)
Topical does not settle interactions or long-term uncertainty. The US label has no clinical interaction studies. Multiple acne products can obscure the cause of irritation; multiple hair drugs obscure benefit attribution. A long personal log cannot establish long-term safety of a concentrated, unverified preparation. WINLEVI (clascoterone) cream: US prescribing information (Official context · Accessed 2026-09-30) · CB-03-01 / Breezula Personal Results (Personal report · Accessed 2026-09-30)
Source context — WINLEVI (clascoterone) cream: US prescribing information: Acne1% cream label, not a5% scalp or15% user-product label. Day5 plateau is not half-life, and maximal-use laboratory findings do not diagnose a forum user's fatigue. Supporting caution/identity only; no formal dose substituted into practical sections.
Source context — CB-03-01 / Breezula Personal Results: One unverified approximately15% research-product account. Product purity, dose, frequency and cortisol suppression not verified. Concurrent treatments and prior RU/pyrilutamide use confound hair and symptom attribution. Vendor and purchase details deliberately excluded from public copy.
Source context — Beware the Winlevi withdrawal: Unverified self-attribution. No medical confirmation of topical steroid withdrawal. The opening says one year later, while TLDR describes six months to heal: prose retains months to recover without reconciling these into a precise duration. One OP and their timeline are one account.
Source context — Talk to me about clascoterone (Winlevi): good, bad and ugly: Self-selected uncontrolled accounts; concurrent skincare, oral spironolactone and changing routines in some reports. Relative timestamps not converted to publication dates. No prevalence inference; a two-day response is one person's perception.
Source context — Winlevi: European Medicines Agency overview: Current EU acne information. Pregnancy restriction and adolescent controls are jurisdiction-specific; no hair-loss approval inferred. Agency statement about growth/puberty outcomes is distinct from biochemical suppression found in the US maximal-use label.
Full notes
Clascoterone is a topical androgen blocker discussed for hormonal acne and hair loss. Acne users describe fewer painful spots, unchanged skin, or irritation; hair users debate whether acne cream can substitute for a scalp solution. Reported benefit depends on the form and often comes alongside other treatments.
What clascoterone actually is
- Winlevi, Breezula and CB-03-01 name the same molecule, not interchangeable products. Also called cortexolone 17α-propionate, it blocks androgen receptors in skin. Winlevi is 1% acne cream; Breezula names the higher-strength scalp-development program. Cream versus solution changes the carrier as well as concentration. Community Official context Official context
- People want hormone-targeted skin or hair effects without an oral drug. Acne discussion centers on recurring chin and jaw breakouts. Hair discussion centers on maintenance without oral finasteride, and comparisons with RU-58841 or pyrilutamide. Topical application does not guarantee that effects stay entirely in the skin. Reddit r/SkincareAddiction Personal report Community
What people hope to notice
- Fewer painful acne spots, sometimes less oil. One commenter described smaller premenstrual jaw pimples and more even nose oil. Another described improved cystic chin acne while still using a separate acne product. Replies also include six weeks or two months without improvement: clearer skin is not everyone's experience. Reddit r/SkincareAddiction
- Hair maintenance is a different claim from regrowth. A long-running forum account describes maintaining hair alongside several treatments. A nightly acne-cream user noticed no hair difference. The 15% solution account describes less shedding, but sleep and energy problems outweighed the perceived benefit. Personal report Personal report Personal report
Doses people discuss
Reported use, not a regimen. A percentage is concentration; it does not specify the amount applied or absorbed.
- 1% acne cream: morning and evening in acne accounts; nightly in one hair experiment. The acne account also used tretinoin and a benzoyl-peroxide wash. The hair commenter used morning minoxidil. Neither supplied grams per application, so a daily milligram total cannot be reconstructed. Reddit r/acne Personal report
- 2% scalp solution: 50 mg in 2.5 mL daily in one older log. This is a reported daily total, not a cream equivalent. Personal report
- 5%, 7.5% and about 15% have different origins. The 5% twice-daily and earlier 2.5% or 7.5% numbers circulate from hair studies and clinic explainers. Separately, one user reported about 15% liquid over the whole scalp; amount and application frequency were unspecified. These do not form a dose ladder. Community Personal report
Half-life
- No dependable community measurement in these accounts. Morning-and-night use is a reported application schedule, not a measured half-life. How long one skin application blocks receptors, blood elimination and how long an improvement lasts are separate questions. Community Reddit r/acne
Onset: when a change is noticed
- Days in some accounts; weeks or no change in others. One acne reviewer noticed improvement within days; another commenter noticed slightly less oil around week four. The concentrated hair-solution user perceived less shedding within days, while the nightly 1% hair user remained unimpressed. Early appearance changes do not establish new hair growth. Personal report Reddit r/SkincareAddiction Personal report Personal report
Duration: how long improvement lasts
- Repeated-use histories do not reveal single-application duration. One acne user initially improved, had about two weeks without new pimples, then relapsed and stopped around month five. Another reviewer reported fewer painful cysts during six months of use. Neither describes a lasting cure after stopping. Reddit r/SkincareAddiction Personal report
Cycles and stopping
- Ongoing use and assessment windows, not a shared on/off cycle. The older hair notes use 3–6-month photo comparisons; one detailed log ran 2.5 years. These are observation periods, not validated course lengths. Acne users stopped for nonresponse or unwanted effects, and stopping experiences differ. No dependable break or restart calendar emerged. Community Personal report Reddit r/SkincareAddiction Personal report
Cautions that matter
- Dryness, redness, itching and burning. Other irritating acne products can add to skin reactions. The US label cautions about damaged skin, large areas and covering treated skin; it reports suppression of the body's cortisol-control system under maximal-use conditions. The 15% user's fatigue does not diagnose that condition. Official context Personal report
- Pregnancy and adolescents require distinct caution. EU information prohibits pregnancy use and restricts adolescent treatment to facial acne with monitoring precautions. Its authorization on 17 October 2025 superseded the earlier refusal while retaining endocrine precautions. Official context
- Topical does not settle interactions or long-term uncertainty. The US label has no clinical interaction studies. Multiple acne products can obscure the cause of irritation; multiple hair drugs obscure benefit attribution. A long personal log cannot establish long-term safety of a concentrated, unverified preparation. Official context Community Personal report
What the detailed accounts add
- A promising start can reverse. The five-month acne account initially blamed an overloaded routine, simplified it, and sounded pleased before reporting relapse. A different commenter stopped after six weeks without benefit and reported no withdrawal. Both timelines matter when reading early enthusiasm. Reddit r/SkincareAddiction
- A severe stopping reaction is reported, not a confirmed diagnosis. One user described three good months, returning acne, then an itchy, red, dry rash three days after stopping. They described prolonged sensitivity and months to recover. Their comparison with topical steroid withdrawal does not establish that diagnosis or show how often it happens. Personal report
- Less shedding did not make the 15% experiment worthwhile. The author described waking during sleep, unrefreshing rest and low daytime energy, then declined a lower-strength retry. They also disclosed ongoing topical finasteride and twice-daily minoxidil. It is one confounded account, not evidence that clascoterone replaced those drugs. Personal report
- Maintenance came with several treatments. In the separate 2.5-year maintenance account, hilbert used clascoterone alongside minoxidil, progesterone, setipiprant and occasional light treatment. They reported normal early hormone tests and fluctuating libido despite unchanged use; this is not the approximately 15% solution author's history. Personal report
- The tube, dropper and comparisons cause practical confusion. Some acne users like the cream texture; others find it thick. Hair conversations compare clinic scalp preparations with pharmacy acne cream, RU and pyrilutamide. A fivefold concentration difference is not a fivefold effectiveness difference, and older minoxidil comparisons do not establish superiority or a finasteride replacement. Reddit r/SkincareAddiction Community Personal report
Product and study context
- US acne labeling: 1% cream, a thin layer twice daily. The label's twice-daily schedule concerns acne cream. It does not establish an application amount or schedule for a different scalp solution. Official context
- Hair-study conditions are separately defined. SCALP2 specified 5% scalp solution, 1.5 mL per application twice daily, for six controlled months, with a separate six-month extension for responders. These are trial conditions, not community measurements or proof that acne cream treats hair loss. Official context
- A blood plateau is not a half-life. The acne label reports stable blood levels by day five during repeated use. That does not give a dependable scalp-effect interval. Official context
- Storage belongs to the finished product. The US cream label specifies room temperature during use and disposal one month after opening or 180 days after dispensing, whichever comes first. That is not a stability rule for a scalp solution. Official context